Sorafenib Tosylate

Indications

Cancer

Sorafenib Tosylate is used to treat patients with unresectable hepatocellular carcinoma (HCC), which means liver cancer that can't be removed by surgery. It is also used to treat patients with advanced renal cell carcinoma (RCC).

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Sorafenib is a kinase inhibitor, and it works by reducing the growth of tumour cells. It has been shown to block several kinases inside the cell (CRAF, BRAF and mutant BRAF) as well as kinases on the cell surface (KIT, FLT-3, RET, VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR-β). Many of these kinases are thought to take part in tumour cell signalling, angiogenesis and apoptosis.

In immunocompromised mice, sorafenib slowed tumour growth and angiogenesis in human hepatocellular carcinoma and renal cell carcinoma. It did the same in several other human tumour xenografts.

Pregnancy & Breastfeeding

Sorafenib may harm an unborn baby if a pregnant woman takes it. This is based on how the medicine works and on what was seen in animal studies. Women who could become pregnant should be told to avoid pregnancy while they are on Sorafenib. Nobody knows yet whether Sorafenib passes into human breast milk.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: The recommended daily dose of Sorafenib is 400 mg tablets taken twice daily without food, which means at least 1 hour before or 2 hours after a meal. Treatment should go on until the patient is no longer getting clinical benefit from the therapy or until unacceptable toxicity occurs. Management of suspected adverse drug reactions may need a temporary interruption and/or a dose reduction of Sorafenib therapy. When the dose has to be reduced, Sorafenib may be lowered to 400 mg once daily. If a further reduction is needed, it may be lowered to a single 400 mg dose every other day. Recommended regimens and treatment duration for Sorafenib therapy are as follows. Grade 1: Numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema or discomfort of the hands or feet which does not disrupt the patient's normal activities. Any occurrence: Continue treatment with Sorafenib and consider topical therapy for symptomatic relief. Grade 2: Painful erythema and swelling of the hands or feet and/or discomfort affecting the patient's normal activities. 1st occurrence: Continue treatment with Sorafenib and consider topical therapy for symptomatic relief. If there is no improvement within 7 days, see below. No improvement within 7 days or 2nd or 3rd occurrence: Interrupt Sorafenib treatment until the toxicity resolves to Grade 0 to 1. When resuming treatment, decrease the Sorafenib dose by one dose level (400 mg daily or 400 mg every other day). 4th occurrence: Discontinue Sorafenib treatment. Grade 3: Moist desquamation, ulceration, blistering or severe pain of the hands or feet, or severe discomfort that leaves the patient unable to work or perform activities of daily living. 1st or 2nd occurrence: Interrupt Sorafenib treatment until the toxicity resolves to Grade 0 to 1. When resuming treatment, decrease the Sorafenib dose by one dose level (400 mg daily or 400 mg every other day). 3rd occurrence: Discontinue Sorafenib treatment. No dose adjustment is needed on the basis of the patient's age, gender or body weight. Missed doses: If a dose of Sorafenib is missed, skip it and take the next dose at the regular time. Do not double your dose of Sorafenib.

Suggest a correction

Sorafenib Tosylate

Indications

Pharmacology

Pregnancy & Breastfeeding

Dosage Reference

Side Effects & Interactions

Side Effects

Key Interactions